Biodesix, Inc. to Announce Results of VeriStrat® Biomarker Study
5/21/2013 11:00:55 AM
More...
|
Biodesix, Inc. Adds $8.8 Million in Financing
4/12/2013 6:55:30 AM
More...
|
Peer-Reviewed Study Confirms VeriStrat® Test From Biodesix, Inc. Provides Useful Information for Physicians in Managing Patients With Lung Cancer
4/2/2013 10:01:06 AM
More...
|
Heinrich Röder of Biodesix, Inc. to Present at 2013 Biomarker Summit
3/18/2013 6:25:49 AM
More...
|
Biodesix, Inc. Release: VeriStrat® Test Predicts Differential Treatment Benefit Between Erlotinib Therapies for Lung Cancer Patients
9/10/2012 9:09:16 AM
More...
|
Biodesix, Inc. Release: VeriStrat® Test Predicts Differential Treatment Benefit Between Chemotherapy and Targeted Therapy for Lung Cancer Patients
9/10/2012 9:07:18 AM
More...
|
Biodesix, Inc. Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
8/27/2012 10:04:15 AM
More...
|
Biodesix, Inc. Appoints Vice President of Clinical Development & Medical Affairs
7/17/2012 9:55:17 AM
More...
|
Biodesix, Inc.' Proteomic Analysis of Innovative Immunotherapy Clinical Trial in Pancreas Cancer Presented at European Society of Medical Oncology's (ESMO) World Congress on Gastrointestinal Cancer
6/27/2012 1:02:27 PM
More...
|
Biodesix, Inc.' Paul Beresford Joins 2012 Biotechnology Industry Organization (BIO) Panel for Personalized Medicine Commercialization
6/5/2012 10:42:07 AM
More...
|
|